![Patient in Hospital - Biosimilars 21st Century Cures 2.0 Request for Information](https://amcp.org/sites/default/files/styles/card_fullsize/public/images/AMCP-biosimilars-patient-stock.jpg.webp?itok=qCO1zJVG)
View AMCP comments to the FDA on considerations in demonstrating biosimilar interchangeability with a biologic reference product.
On Aug. 13, AMCP joined dozens of national and state advocacy organizations in a sign-on letter calling on House and Senate leadership to strengthen patients’ access to high-quality health coverage and care. Specifically, the letter urges Congress to support 12-month continuous eligibility for adults in Medicaid and the Children’s Health Insurance Program (CHIP) by passing the Stabilize Medicaid and CHIP Coverage Act (H>R. 5434/S. 3138).
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.